Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRT3645

Small molecule · Inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6) · developed by Prelude Therapeutics

Phase 1 Most advanced trial (none active)
PRLD Developer
1 Registered trials

What is PRT3645?

PRT3645 is an orally bioavailable, brain-penetrant small molecule that selectively inhibits the kinases CDK4 and CDK6. By blocking Rb phosphorylation in early G1, it arrests the cell cycle and reduces tumor cell proliferation. It is being studied in breast cancer, glioblastoma, head and neck squamous cell carcinoma, malignant mesothelioma, non-small cell lung cancer, sarcoma and endometrial cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Targets
cyclin-dependent kinase 4 (CDK4), cyclin-dependent kinase 6 (CDK6)
Mechanism
Inhibitor of cyclin-dependent kinase 4 (CDK4) and cyclin-dependent kinase 6 (CDK6)
Pathways
Rb phosphorylation, G1-S cell cycle transition, DNA replication
Therapy area
Oncology
Developer
Prelude Therapeutics Incorporated (PRLD)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05538572 Phase 1 Breast Cancer Completed PRLD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Breast CancerEndometrial CancerGlioblastomaHead and Neck Squamous Cell CarcinomaMalignant MesotheliomaNon-small Cell Lung CancersSarcoma

Other drugs acting on CDK4 / CDK6

More from Prelude Therapeutics

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.

Follow PRLD, the company behind PRT3645

See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRLD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.